|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C16orf13 |
Gene summary for C16ORF13 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C16orf13 | Gene ID | 84326 |
| Gene name | methyltransferase like 26 | |
| Gene Alias | C16orf13 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q96S19 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84326 | C16orf13 | P1T-E | Human | Esophagus | ESCC | 2.53e-37 | 1.56e+00 | 0.0875 |
| 84326 | C16orf13 | P2T-E | Human | Esophagus | ESCC | 3.21e-118 | 1.85e+00 | 0.1177 |
| 84326 | C16orf13 | P4T-E | Human | Esophagus | ESCC | 7.47e-101 | 2.16e+00 | 0.1323 |
| 84326 | C16orf13 | P5T-E | Human | Esophagus | ESCC | 1.95e-125 | 2.21e+00 | 0.1327 |
| 84326 | C16orf13 | P8T-E | Human | Esophagus | ESCC | 1.03e-89 | 1.53e+00 | 0.0889 |
| 84326 | C16orf13 | P9T-E | Human | Esophagus | ESCC | 1.27e-65 | 1.30e+00 | 0.1131 |
| 84326 | C16orf13 | P10T-E | Human | Esophagus | ESCC | 1.68e-101 | 1.45e+00 | 0.116 |
| 84326 | C16orf13 | P11T-E | Human | Esophagus | ESCC | 2.49e-61 | 1.80e+00 | 0.1426 |
| 84326 | C16orf13 | P12T-E | Human | Esophagus | ESCC | 4.10e-109 | 1.84e+00 | 0.1122 |
| 84326 | C16orf13 | P15T-E | Human | Esophagus | ESCC | 3.77e-94 | 1.74e+00 | 0.1149 |
| 84326 | C16orf13 | P16T-E | Human | Esophagus | ESCC | 4.93e-91 | 1.39e+00 | 0.1153 |
| 84326 | C16orf13 | P17T-E | Human | Esophagus | ESCC | 2.76e-57 | 1.72e+00 | 0.1278 |
| 84326 | C16orf13 | P19T-E | Human | Esophagus | ESCC | 4.55e-30 | 2.10e+00 | 0.1662 |
| 84326 | C16orf13 | P20T-E | Human | Esophagus | ESCC | 2.74e-93 | 1.67e+00 | 0.1124 |
| 84326 | C16orf13 | P21T-E | Human | Esophagus | ESCC | 5.90e-142 | 2.65e+00 | 0.1617 |
| 84326 | C16orf13 | P22T-E | Human | Esophagus | ESCC | 1.36e-138 | 2.25e+00 | 0.1236 |
| 84326 | C16orf13 | P23T-E | Human | Esophagus | ESCC | 1.60e-91 | 1.88e+00 | 0.108 |
| 84326 | C16orf13 | P24T-E | Human | Esophagus | ESCC | 3.45e-97 | 1.57e+00 | 0.1287 |
| 84326 | C16orf13 | P26T-E | Human | Esophagus | ESCC | 9.31e-122 | 1.76e+00 | 0.1276 |
| 84326 | C16orf13 | P27T-E | Human | Esophagus | ESCC | 5.87e-84 | 1.25e+00 | 0.1055 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |